SAN DIEGO, Jan. 12 SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has established an Advisory Board to assist and direct management in facing requirements of a changing heath care system.
Governor Thompson stated, "My charter for the Advisory Board will be to detect how our changing health care system might have an affect on the Company. We have to be prepared to anticipate and react to shifting conditions. I will work closely with management and other Advisory Board members to steer the Company to the most advantageous outcome. I enjoy serving with SpectraScience and have the utmost respect for the Company."
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward- looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to illuminate tissue and provides the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. In addition, the Company's LUMA® Cervical Imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available today.
Contact: SpectraScience, Inc. Hayden Communications Jim Hitchin, Chief Executive Officer Investor Relations (858) 847-0200 x 201 Todd Pitcher http://www.spectrascience.com (858)-518-1387
SOURCE SpectraScience, Inc.